Separately, Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the stock a buy rating in a research report on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cellular Biomedicine Group currently has an average rating of Buy and an average target price of $27.50.
Shares of NASDAQ CBMG opened at $14.38 on Friday. The stock’s 50 day simple moving average is $14.87. Cellular Biomedicine Group has a twelve month low of $12.04 and a twelve month high of $25.00.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. The firm had revenue of $0.05 million for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. Equities analysts forecast that Cellular Biomedicine Group will post -2.08 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co. NY bought a new stake in shares of Cellular Biomedicine Group during the fourth quarter worth approximately $81,000. Nikko Asset Management Americas Inc. bought a new stake in shares of Cellular Biomedicine Group during the first quarter worth approximately $6,721,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Cellular Biomedicine Group by 1,641.8% during the first quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 2,315 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Cellular Biomedicine Group during the fourth quarter worth approximately $110,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Cellular Biomedicine Group by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 126,067 shares of the biotechnology company’s stock worth $2,226,000 after acquiring an additional 14,621 shares during the period. 17.87% of the stock is currently owned by hedge funds and other institutional investors.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Further Reading: Why is cost of goods sold important?
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.